Taisho Pharmaceutical Holdings Co (TSE:4581) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Taisho Pharmaceutical Holdings Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Taisho Pharmaceutical Holdings Co's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Taisho Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Chart

Taisho Pharmaceutical Holdings Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Taisho Pharmaceutical Holdings Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Taisho Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Calculation

Taisho Pharmaceutical Holdings Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0	/	941490
	=	0.00

Taisho Pharmaceutical Holdings Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	1005463
	=	0.00

Taisho Pharmaceutical Holdings Co (TSE:4581) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Taisho Pharmaceutical Holdings Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TAIPY:USA TAISF:USA

Address

3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655

Website

http://www.taisho-holdings.co.jp

Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines